India Globalization Capital, Inc. (IGC) is engaged in the development of cannabinoid-based therapies for indications such as Alzheimer's disease and pain. IGC operates through two segments: Life Sciences and Infrastructure. Life Sciences segment involves the development of potential new drugs, hand sanitizers and several hemp-based Cannabidiol (CBD) products and brands, wholesale of hemp extracts, including hemp crude extract and hemp isolate, among others, white labeling of hemp-based products, and offering of tolling services like extraction and distillation to hemp farmers. Infrastructure segment involves execution of construction contracts, rental of heavy construction equipment and purchase and resale of physical commodities used in infrastructure. IGC'S Life Sciences brands include Hyalolex, Holi Hemp, Holief, Herbo, and Sunday Seltzer.
No insider trading activity.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.